Prelude Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Prelude Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-12,000	Closed	-$1.48M	–	1615
2015 Q2	$1.48M	Buy	+12,000	New	+$1.44M	0.21%	131
2013 Q4	–	Sell	-4,500	Closed	-$314K	–	1744
2013 Q3	$314K	Buy	+4,500	New	+$295K	0.05%	404

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's IBB Position: Q4 2017 in Review

Prelude Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2017, closing a stake of 792 shares — an estimated $88K sold.

Prelude Capital Management first reported a position in IBB in Q4 2015 and held it in 4 quarters. The position peaked at $1.69M in Q4 2015. 624 funds tracked by Wall St. Rank hold IBB as of Q4 2017.

Prelude Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 792 iShares Biotechnology ETF shares in Q4 2017, an estimated $88K.
Prelude Capital Management first reported a position in iShares Biotechnology ETF in Q4 2015 and held it in 4 quarters.
Prelude Capital Management's iShares Biotechnology ETF position peaked at $1.69M in Q4 2015.
624 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.